Wiley has announced the release of its 2025 edition of the Mass Spectra of Designer Drugs database, a critical resource expanding forensic laboratories’ capabilities in the identification of illicit substances. The updated database represents a substantial advancement in analytical tools available to forensic scientists combating the proliferation of novel psychoactive substances.
A state-of-the-art pilot line environment established by VTT Technical Research Centre of Finland aims to bridge the critical gap between medical technology research and market-ready products, potentially reducing development timelines for non-invasive diagnostic and monitoring devices.
Therapeutic drug monitoring is used for a number of reasons. The usual techniques include immunoassay and mass spectrometry, both of which have limitations. CLI chatted to Dr Pin Dong (University of York, York, UK) to discuss the potential for Fourier transform infrared spectroscopy to bridge the gap and provide high specificity measurements with a fast […]
Rice University bioengineers have developed the smallest free-floating gas-filled structures for medical imaging, potentially revolutionising ultrasound technology and targeted drug delivery.
The European Laboratory Research & Innovation Group (ELRIG) UK and The Protein Society (TPS) have announced a partnership aimed at advancing protein sciences in drug discovery. This collaboration will culminate in a joint conference, ‘Protein Sciences in Drug Discovery’, scheduled for 18-19 November 2024 in Cambridge, UK.
Researchers at the Fraunhofer Institute for Biomedical Engineering IBMT have developed innovative solutions for the production and preservation of human induced pluripotent stem (hiPS) cells, potentially revolutionising drug discovery and toxicity testing processes.
PrecisionLife, a leading techbio company driving precision medicine into complex chronic diseases, and Nanopharmaceutics, a clinicalstage pharmaceutical development company, have established a strategic collaboration aiming to accelerate and de-risk the development of Nanopharmaceutics’ portfolio of central nervous system (CNS) assets.
ProBioGen has agreed a multi-product commercial license with AstraZeneca to use the GlymaxX technology.
April | May 2025
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.